Erschienen in:
17.07.2023 | Scientific Letter
Ondansetron as a Supportive Therapeutic Agent for Severe Pruritus in Pediatric Patients with Chronic Cholestasis
verfasst von:
Nehal M. El-koofy, Mohamed A. Elmonem, Mai El-Mahdy, Sawsan Okasha, Afaf Enayet
Erschienen in:
Indian Journal of Pediatrics
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: Pruritus is a devastating and difficult to control feature of pediatric-chronic-cholestasis and intractable-pruritus can be the sole-indication for liver-transplantation. Pruritus pathophysiology is not well-understood, but is driven by chronic inflammation stimulated by various pruritogens, such as bile-salts, steroid-hormones, histamine, endogenous-opioids, and serotonin [
1]. Ondansetron is a 5-hydroxy-tryptamine 3 (5-HT3) receptor-antagonist, that is used to combat emesis and was proposed as a potential-therapy for pruritus [
2]. We evaluated the efficacy and side-effects of orodispersible ondansetron for the first time as a supportive-treatment for severe-pruritus in chronic-cholestatic-children. …